Eli Lilly halts COVID-19 antibody treatment trial over safety issues
Category: #headlines  By Nikita Chaurasia  Date: 2020-10-15
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly halts COVID-19 antibody treatment trial over safety issues

 

  • The announcement comes along the heels of a sudden spike in the number of coronavirus cases across U.S.
  • Eli Lilly’s shares dropped by about 3% after it halted the COVID-19 antibody trials.

Eli Lilly and Company, an American pharmaceutical company, has reportedly announced that it has paused its government sponsored COVID-19 antibody treatment trial over safety concerns. Sources close to the matter stated that the announcement comes along the heels of a sudden spike in the number of coronavirus cases across United States.

For the record, Eli Lilly’s COVID-19 antibody study will focus on the benefits of the therapy on various patients suffering from the novel coronavirus. Besides the potential antibody, each participant has reportedly also received an experimental drug called remdesivir which is commonly used to treat COVID-19 patients.

It is to be noted that the company had recently requested for an EUA (emergency use authorization) for its antibody LY-CoV555 from the U.S. Food & Drug Association (FDA). However, the exact safety concerns which halted the trials remain unclear, sources claimed.

Molly McCully, a spokesperson from Eli Lilly mentioned in a comment that the ACTIV-3 data safety monitoring board (DSMB) suggested the company to halt the trials. She further added that the Eli Lilly supported the decision made by the independent DSMB for the wellbeing of the study participants.

According to industry experts, such pauses during large scale clinical trials are not an uncommon instance and the decline in the volunteer’s health is not necessarily due to the vaccine or an experimental drug. In fact, such study halts enable scientific experts to review the data generated during the trials.

Eli Lilly’s shares dropped by about 3% after it halted the COVID-19 antibody trials, cited sources with relevant information.

In other news, another American pharmaceutical company, Johnson & Johnson, had reportedly paused its study for COVID-19 antibody candidate after one of the trial participants witnessed an unexpected illness.

Source- https://www.aljazeera.com/economy/2020/10/13/eli-lilly-pauses-covid-19-antibody-trial-due-to-safety-concern

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...